{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:12:48Z","timestamp":1790723568184,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T00:00:00Z","timestamp":1546041600000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000448"],"award-info":[{"award-number":["UL1TR000448"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["T32HD043010101"],"award-info":[{"award-number":["T32HD043010101"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["RC2AR058934"],"award-info":[{"award-number":["RC2AR058934"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12969-018-0299-9","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T07:26:03Z","timestamp":1546068363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis"],"prefix":"10.1186","volume":"16","author":[{"name":"for the CARRA Legacy Registry Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-2402","authenticated-orcid":false,"given":"Amir B.","family":"Orandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas R.","family":"Dharnidharka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Al-Hammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Baszis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,29]]},"reference":[{"issue":"3","key":"299_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases registry. Arthritis Rheum. 2003;49(3):300\u20135.","journal-title":"Arthritis Rheum"},{"key":"299_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-3476(64)80325-5","volume":"64","author":"S Bitnum","year":"1964","unstructured":"Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr. 1964;64:101\u201331.","journal-title":"J Pediatr"},{"issue":"2 Suppl","key":"299_CR3","first-page":"327","volume":"20","author":"DB Sullivan","year":"1977","unstructured":"Sullivan DB, Cassidy JT, Petty RE. Dermatomyositis in the pediatric patient. Arthritis Rheum. 1977;20(2 Suppl):327\u201331.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"299_CR4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1542\/peds.59.2.212","volume":"59","author":"JC Jacobs","year":"1977","unstructured":"Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics. 1977;59(2):212\u20138.","journal-title":"Pediatrics"},{"issue":"1","key":"299_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.20015","volume":"62","author":"A Ravelli","year":"2010","unstructured":"Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63\u201372.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"299_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/03009742.2011.608376","volume":"41","author":"P Mathiesen","year":"2012","unstructured":"Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012;41(1):50\u20138.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"299_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0889-857X(02)00024-8","volume":"28","author":"AV Ramanan","year":"2002","unstructured":"Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin N Am. 2002;28(4):833\u201357.","journal-title":"Rheum Dis Clin N Am"},{"issue":"3","key":"299_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","volume":"43","author":"AM Huber","year":"2000","unstructured":"Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541\u20139.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"299_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11926-014-0467-y","volume":"16","author":"MF Hoeltzel","year":"2014","unstructured":"Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16(12):467.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"299_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12969-017-0199-4","volume":"15","author":"AB Orandi","year":"2017","unstructured":"Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, subgroup CJM. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"2","key":"299_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jpeds.2005.10.032","volume":"148","author":"LM Pachman","year":"2006","unstructured":"Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148(2):247\u201353.","journal-title":"J Pediatr"},{"issue":"5","key":"299_CR12","first-page":"782","volume":"28","author":"PR Mathiesen","year":"2010","unstructured":"Mathiesen PR, Zak M, Herlin T, Nielsen SM. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol. 2010;28(5):782\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"299_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1067\/mjd.2002.122196","volume":"47","author":"RE Fisler","year":"2002","unstructured":"Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"299_CR14","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/art.24571","volume":"60","author":"S Kim","year":"2009","unstructured":"Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60(6):1825\u201330.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"299_CR15","doi-asserted-by":"publisher","first-page":"A65","DOI":"10.1186\/1546-0096-10-S1-A65","volume":"10","author":"MF Hoeltzel","year":"2012","unstructured":"Hoeltzel MF. Race is a risk factor for calcinosis in patients with JD - early results from the CARRAnet registry study. Pediatr Rheumatol. 2012;10(Suppl 1):A65.","journal-title":"Pediatr Rheumatol"},{"key":"299_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1546-0096-12-2","volume":"12","author":"G Faller","year":"2014","unstructured":"Faller G, Mistry BJ, Tikly M. Juvenile dermatomyositis in south African children is characterised by frequent dystropic calcification: a cross sectional study. Pediatr Rheumatol Online J. 2014;12:2.","journal-title":"Pediatr Rheumatol Online J"},{"key":"299_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","volume":"184","author":"K Phillippi","year":"2017","unstructured":"Phillippi K, Hoeltzel M, Byun Robinson A, Kim S, Childhood A. Rheumatology research Alliance legacy registry I. race, income, and disease outcomes in juvenile dermatomyositis. J Pediatr. 2017;184:38\u201344 e1.","journal-title":"J Pediatr"},{"issue":"7","key":"299_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00296-016-3467-6","volume":"36","author":"I Saini","year":"2016","unstructured":"Saini I, Kalaivani M, Kabra SK. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int. 2016;36(7):961\u20135.","journal-title":"Rheumatol Int"},{"issue":"1","key":"299_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1590\/S0021-75572008000100012","volume":"84","author":"AM Sallum","year":"2008","unstructured":"Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr. 2008;84(1):68\u201374.","journal-title":"J Pediatr"},{"issue":"6","key":"299_CR20","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.24547","volume":"60","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807\u201314.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"299_CR21","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","volume":"53","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford). 2014;53(12):2204\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"299_CR22","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","volume":"43","author":"LM Pachman","year":"2000","unstructured":"Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43(10):2368\u201377.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"299_CR23","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1002\/art.24039","volume":"58","author":"G Mamyrova","year":"2008","unstructured":"Mamyrova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 2008;58(12):3941\u201350.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"299_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1590\/S0482-50042012000400007","volume":"52","author":"G Clemente","year":"2012","unstructured":"Clemente G, Piotto DG, Barbosa C, Peracchi OA, Len CA, Hilario MO, et al. High frequency of calcinosis in juvenile dermatomyositis: a risk factor study. Rev Bras Reumatol. 2012;52(4):549\u201353.","journal-title":"Rev Bras Reumatol"},{"issue":"6","key":"299_CR25","first-page":"R10-R","volume":"37","author":"AM Callen","year":"1994","unstructured":"Callen AM, Pachman LM, Hayford J, Chung A, Ramseygoldman R. Intermittent high-dose intravenous methylprednisolone (iv pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis (Jdms). Arthritis Rheum. 1994;37(6):R10-R.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"299_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jpeds.2009.09.008","volume":"156","author":"DM Levy","year":"2010","unstructured":"Levy DM, Bingham CA, Kahn PJ, Eichenfield AH, Imundo LF. Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids. J Pediatr. 2010;156(2):302\u20137.","journal-title":"J Pediatr"},{"issue":"4","key":"299_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1090-3798(98)80021-4","volume":"2","author":"B Tabarki","year":"1998","unstructured":"Tabarki B, Ponsot G, Prieur AM, Tardieu M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol. 1998;2(4):205\u201311.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"299_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acr.22142","volume":"66","author":"AB Robinson","year":"2014","unstructured":"Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood arthritis and rheumatology research Alliance registry. Arthritis Care Res (Hoboken). 2014;66(3):404\u201310.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"6","key":"299_CR29","first-page":"1198","volume":"25","author":"LM Pachman","year":"1998","unstructured":"Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25(6):1198\u2013204.","journal-title":"J Rheumatol"},{"issue":"8","key":"299_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s10067-014-2675-2","volume":"33","author":"A Malek","year":"2014","unstructured":"Malek A, Raeeskarami SR, Ziaee V, Aghighi Y, Moradinejad MH. Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis. Clin Rheumatol. 2014;33(8):1113\u20138.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"299_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223\u201343.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"299_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","volume":"87","author":"A Bingham","year":"2008","unstructured":"Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87(2):70\u201386.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"299_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","volume":"47","author":"P Riley","year":"2008","unstructured":"Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"299_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12969-017-0160-6","volume":"15","author":"T Beukelman","year":"2017","unstructured":"Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, et al. The new Childhood arthritis and rheumatology research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J. 2017;15(1):30.","journal-title":"Pediatr Rheumatol Online J."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-018-0299-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0299-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T07:18:42Z","timestamp":1662707922000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-018-0299-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1186\/s12969-018-0299-9","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"4 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was exempt from review by the Washington University Institutional Review Board by not constituting human subject research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"84"}}